Jeffrey Nau - Jan 9, 2022 Form 4 Insider Report for Oyster Point Pharma, Inc. (OYST)

Role: President and CEO, Director
Signature: /s/ Brandon Fenn, Attorney-in-Fact
Stock symbol: OYST
Transactions as of: Jan 9, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/11/2022, 06:46 PM
Previous filing: Oct 22, 2021
Next filing: Jan 4, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OYST	Common Stock	Award	$0	+46.7K	+42.11%	$0.00	158K	Jan 9, 2022	Direct	F1, F2
holding	OYST	Common Stock						1K	Jan 9, 2022	See Footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OYST	Employee Stock Option (Right to Buy)	Award	$0	+210K		$0.00	210K	Jan 9, 2022	Common Stock	210K	$16.00	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
F2	25% of the RSUs vest on January 7, 2023 and the remainder vest annually thereafter, in equal amounts, on the same day of the month as the grant date over the following 3 years, subject to the Reporting Person's continuous service to the Issuer through each such date.
F3	These shares are held by the Reporting Person's spouse.
F4	Options granted on January 9, 2022 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 25% of the options shall vest and become exercisable on January 7, 2023 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date.